As in other organ systems, gene and drug delivery to ocular tissues such as the retina and cornea is hampered by inefficient penetration of therapeutic molecules across the plasma membrane. We describe the use of a novel peptide for ocular delivery (POD) with protein transduction properties, for delivery of small and large molecules across the plasma membrane. POD enters cells within 5 minutes in a temperature dependent manner. POD can compact and deliver plasmid DNA, achieving transgene expression in >50% of human embryonic retinoblasts. Delivery of small interfering RNA (siRNA) duplexes to cells using POD, allowed for silencing of transgene expression by >50%. POD could also be used to deliver quantum dots in vitro and in vivo. Upon ocular delivery, POD rapidly entered neural retina and localized to retinal pigment epithelium (RPE), photoreceptor, and ganglion cells. Additionally, POD was able to enter corneal epithelium, sclera, choroid, and the dura of the optic nerve via topical application. POD also functions as a bacteriostatic, a useful property for a carrier of molecules to post mitotic neural ocular tissues.
INTRODUCTION
According to the National Institute of Health, ocular diseases that lead to blindness are one of the most common causes of disability in the United States. 1 Some common diseases of the retina include age-related macular degeneration (AMD), retinitis pigmentosa and glaucoma, which are associated with degeneration of the retinal pigment epithelium (RPE), photoreceptors, and retinal ganglion cells, respectively. 2, 3 Infections, dystrophies, or rejection of transplanted corneas are also amongst the common causes of vision loss. 4 Improvements in healthcare that have increased human life expectancy ironically result in a signi cant increase in the frequency of diseases such as AMD or extend the burden associated with currently untreatable diseases such as retinitis pigmentosa. 1 erefore, the need to develop gene and drug delivery technologies for treatment of genetic and acquired ocular disorders is considerable.
As in other tissues, proteins, or drugs directed at intracellular ocular targets need to be su ciently polar to be easily administered. 5 However, for the majority of such molecules, the plasma membrane represents an impermeable barrier. Remarkably, a few select proteins such as the human immunode ciency virus Tat, 6 herpes simplex virus VP22, 7 and the Drosophila melanogaster Antennapedia homeodomain 8 possess the ability to traverse intact biological membranes. Interrogation of the structures of such proteins has led to the hypothesis that these proteins contain modules that confer the property of "protein transduction" and hence such sequences are generally referred to as protein transduction domains (PTDs) as reviewed in ref. 9 . PTDs can be isolated and incorporated into heterologous proteins and peptides, conferring novel protein transduction properties to such recombinant molecules. Initial experiments by several groups on the use of PTDs generated con icting data and substantial debate regarding their properties and mode of action. 10, 11 Some of the issues addressed were whether the phenomenon of protein transduction was in fact real or only an artifact of xation and whether the transduction was receptor, energy, and/or temperature dependent. 12 In agreement with many other investigators studying PTDs, we have previously demonstrated that the PTD of both human immunode ciency virus Tat 13 and herpes simplex virus VP22 14 have valid transduction properties, at least in ocular cell lines and tissues.
e goal of the current study was to examine whether the novel peptide GGG(ARKKAAKA) 4 , MW = 3.5 kd that has not previously been shown to have PTD properties can e ciently deliver small molecules, including uorescent probes and siRNA, and large molecules, including plasmid DNA and quantum dots, to cells in culture and to murine ocular tissues in vivo. Our results indicate that GGG(ARKKAAKA) 4 is an e cient "peptide for ocular delivery (POD)" of small and large molecules across the plasma membrane, both in vitro and in vivo and hence may have potential for the delivery of genes and drugs to human ocular tissues.
(emission measured at 583 nm) within 1 minute but appeared normal in bright eld (Figure 1a) . Within 5 minutes, L-POD was seen within the cytoplasm with both a di use cytoplasmic and slightly punctate pattern (Figure 1a ). e majority of cells showed cytoplasmic staining a er 60 minutes. Furthermore, there was no evidence of uptake of lissamine only (inset, Figure 1a) . Cells that were not xed, i.e., live cells, showed a similar rate of L-POD uptake but with a pattern of localization that was almost exclusively punctate at both 15 minutes and 60 minutes. Again, there was no evidence of uptake of lissamine only (Figure 1b) .
To determine whether L-POD was internalized and not simply associated with the plasma membrane, HER cells incubated with 2 nmol (8 µmol/l) L-POD for 15 minutes were treated with trypsin at 37 °C prior to counting of lissamine-positive cells by uorescence-activated cell sorting (FACS). A total of 90.10 1.89% or 92.23 0.65% of cells were lissamine-positive with or without incubation with trypsin, respectively (Figure 1c) , supporting the hypothesis that the majority of L-POD was internalized and not membrane associated. e sensitivity of POD peptide to trypsinmediated digestion was con rmed by incubation of 2.5 nmol of cysteine-containing POD (C-POD) with trypsin prior to loading on an acrylamide gel (inset, Figure 1c) . Whereas 92.23 0.65% of HER cells were lissamine-positive when incubated with L-POD at 37 °C, only 48.74 2.32% of cells were lissamine-positive when incubated with L-POD at 4 °C (Figure 1d) . Hence, uptake of L-POD is temperature dependent.
In order to determine whether uptake of POD required plasma membrane disruption, we incubated HER cells with increasing concentrations (0.2-2.0 µmol/l) of uorescein isothiocyanateconjugated POD (F-POD) followed by a FACS measurement of the number of permeabilized cells by incubation with propidium iodide (PI). In this experiment F-POD rather than L-POD was utilized to reduce bleed of the lissamine-signal into that of PI. An average of 3.98 0.70% of cells were PI-positive when preincubated with F-POD, similar to the number of PI-positive cells in the absence of any peptide-5.18 3.00% (Figure 1e ). In contrast, 91.44 9.66% were PI-positive when incubated with the cell permeabilizing detergent, 1% Triton-X100 (Figure 1e) . We conclude that F-POD enters HER cells without substantially disrupting the plasma membrane.
POD-mediated delivery of small and large molecules in cell culture
We examined the potential use of an N terminal-biotinylated POD (B-POD) peptide or an N terminal C-POD peptide in delivering small and relatively large molecules to cells in culture. To establish proof-of-principle, we decided to deliver siRNA, plasmid DNA and streptavidin-coated CdSe quantum dots. e use of biotin was to allow the future conjugation of a large variety of biologically relevant compounds to POD via a streptavidin bridge, as we show here for quantum dots, or direct chemical linkage to cysteine is possible through the free sul ydryl bond. First, we electrostatically conjugated C-POD with a 5.5 kilobase plasmid containing a red uorescent protein (RFP) expression cassette (pCAGRFP) and demonstrated that C-POD could compact DNA and prevent its migration in an agarose gel and that the DNA could be liberated by trypsin-digestion of the complex (inset, Figure 2a) . Such complexes prepared in 5% dextrose were incubated with HER 911 cells and analyzed by FACS 48 hours later. pCAGRFP alone or pCAGRFP complexed with C-POD resulted in only 2.45 0.31% and 2.20 0.46% RFP-positive cells, respectively (Figure 2a) . In contrast, when pCAGRFP was complexed with C-POD in Na 2 HPO 4 bu er, 55.58 8.23% of HER cells were RFPpositive. pCAGRFP without C-POD in Na 2 HPO 4 bu er resulted in only 3.80 2.86% RFP-positive cells (Figure 2a) indicating that C-POD and the speci c bu er were important components of the gene delivery complex. Examination of C-POD/pCAGRFP complexes in the two di erently performing bu ers by electron microscopy indicated that complexes prepared in Na 2 HPO 4 had an average area of 63.31 nm 2 , while those prepared in dextrose were 29.66 nm 2 ( Figure 2b ). is di erence may in part play a role in the di erent rates of gene transfer in the two bu ers.
C-POD was subsequently used to deliver a plasmid containing an expression cassette for green uorescent protein (pEGFP) to HER cells, resulting in 49.13 2.23% GFP-positive cells as determined by FACS analysis (Figure 2c) . Transfected cells were then incubated with either free siRNA duplex or siRNA duplex complexed with C-POD, resulting in 39.86 2.20% and 24.79 1.18% GFP-positive cells, respectively (Figure 2c) . is indicates that delivery of siRNA by C-POD is enhanced as compared to that of siRNA alone and that this approach may be a useful method for delivery of siRNA to enhance the knock down of gene expression.
To examine the potential of delivering larger cargo with POD, we conjugated B-POD with streptavidin-coated quantum dots (QDPOD). HER cells incubated with QDPOD resulted in QDPOD-associated uorescence within 15 minutes. QDPOD was also found in a punctate pattern within cells at 120 minutes (Figure 2d ). In contrast, streptavidin-coated quantum dots without B-POD were not taken up by HER cells (Figure 2e ).
Uptake of POD is inhibited by proteoglycans and POD has bacteriostatic activity
In order to determine whether L-POD uses cell-surface proteoglycans for binding and cell entry, we pre-incubated L-POD with varying ratios of either chondroitin sulfate or heparan sulfate prior to addition of the presumed complex to HER cells. Based on preliminary studies, we arbitrarily selected ratios of L-POD: proteoglycan of 1:3.33, 1:6.67, and 1:8. Without pre-incubation of L-POD with any proteoglycan, 90.07 ± 0.64 % of cells were lissamine-positive, whereas increasing ratios of chondroitin sulfate led to a decrease in uptake of L-POD to 71.24 ± 1.77%, 59.43 ± 1.55%, and 34.38 ± 3.13% at 1:3.33, 1:6.67, and 1:8 molar ratios, respectively (Figure 3a) . Similarly, pre-incubation of L-POD with heparan sulfate reduced uptake to 78.60 ± 0.35%, 57.78 ± 2.83%, and 44.37 ± 2.17% respectively at the same ratios described above (Figure 3a) . In contrast, the uptake of a tetramethylrhodamine isothiocyanate-conjugated peptide containing an integrin-binding RGD motif was not a ected by pre-incubation with either proteoglycan (Figure 3a) .
Since endophthalmitis, an infection within the eye, regularly acts as a complicating factor in drug delivery to ocular tissues, 16 we examined the potential bacteriostatic activities of C-POD. Escherichia coli grown to mid-log phase were incubated with either H 2 O only or C-POD suspended in H 2 O at concentrations ranging from 0.03 to 60 µmol/l prior to plating on Luria-Bertani agar. A signi cant inhibition of bacterial growth was observed at C-POD concentrations of 0.30 µmol/l (Figure 3b) , and almost complete inhibition at 24.0 µmol/l C-POD. Greater concentrations of C-POD completely eliminated bacterial growth (data not shown). Hence, we conclude that C-POD has bacteriostatic activity and that it is concentration dependent.
POD-mediated delivery of small and large molecules to retina in vivo
Delivery of L-POD into the subretinal space (a space created between the photoreceptors and the RPE following delivery of uids) of adult C57BL/6J mice followed by harvesting of tissue 2 hours later resulted in ~40% transduction of neural retina (Figure 4a, 4) . Within this region, there was substantial transduction of several layers of the retina including the RPE (Figure 4a, 20) . Closer examination reveals signi cant transduction of photoreceptor cell bodies, photoreceptor inner segments, cells in the inner nuclear layer and ganglion cells (Figure 4a, 40) . Although nuclei were not strongly positive in the cell culture experiments described above, in vivo transduction of retina indicated that L-POD localized to nuclei in the case of RPE transduction (arrowheads, Figure 4a, 40) . As the nuclei of photoreceptor cells are large relative to the cell body, nuclear versus cytoplasmic localization could not be di erentiated for those cells.
Delivery of L-POD into the intravitreal space (the region between the lens and retina) transduced ~85% of the neural retina (Figure 4b, 4) within 2 hours. Strong staining was seen in the ganglion cell layer, inner plexiform layer and inner nuclear layer (Figure 4b, 20) . Closer examination revealed signi cant transduction of the ganglion cells and dendrites associated with the inner plexiform layer (arrowheads, Figure 4b, 40) . ere was no signi cant transduction of the outer layers of the retina by intravitreal injection at the 2 hour time point. Whether transduction of inner layers of the retina in addition to the outer layers following subretinal delivery was due to leakage of L-POD from the subretinal space into the vitreous, or to direct penetration of the retina by L-POD within 2 hours could not be determined. A er 20 hours, L-POD accumulated almost exclusively in the outer nuclear layer and RPE a er subretinal administration, or the inner layers of the retina including ganglion cells a er intravitreal injection (Figure 4c) . Lissamine only injected into either the subretinal or intravitreal space did not penetrate the retina at either 2 or 20 hours (Figure 4d) .
In contrast to L-POD, delivery of the signi cantly larger QDPOD complexes into the subretinal or intravitreal space appeared to permit cell binding but not uptake per se in the 2 hour time period following injection ( Figure 5 ). However, a longer incubation period of 20 hours revealed uptake of QDPOD into the outer nuclear layer following subretinal injection, or into the inner layers of the retina upon intravitreal injection ( Figure 5) . In contrast, the control quantum dots that were coated with streptavidin only, showed only weak uptake by the RPE in 2 hours and slightly greater but still minimal uptake in 20 hours by the RPE (insets, Figure 5 ).
POD-mediated delivery of cargo to ocular tissues by topical application in vivo
Delivery of drugs to ocular tissues via topical administration to the cornea is common practice, with drainage of large amounts of the drug occurring via the lacrimal ducts. In order to assess penetration of the cornea and sclera with L-POD, we topically applied 10 nmol L-POD to the mouse eye in vivo for 45 minutes followed by harvesting of ocular tissues. We found that within 45 minutes, L-POD bound strongly to the cornea, sclera and unexpectedly, also the dura of the optic nerve in vivo (Figure 6a) . In contrast, lissamine only weakly stained the cornea and sclera and did not stain the dura of the optic nerve (Figure 6a) . Frozen cross-sections of these eyes revealed that the entire outer ocular surface was positive for L-POD in contrast to lissamine, which only weakly stained these tissues (Figure 6b) . Closer examination of cornea and sclera indicated that there was strong staining of the corneal epithelium and sclera/choroid within this 45 minute time period (Figure 6c) . In ~50% of animals, the L-POD associated signal was persistent at 24 hours (inset, Figure 6c ). However the signal at this later time point was weaker and seemed to occur deeper in the cornea. Longitudinal and cross-sections of the optic nerve indicated that the outer layers of the optic nerve were transduced with L-POD (Figure 6d) at the 45 minute time point. ere was no staining observed with lissamine only (Figure 6d) in similar experiments. e L-POD associated signal in these tissues did not persist substantially at 24 hours (data not shown).
DISCUSSION
One goal of this study was to identify a peptide that would act e ciently as a PTD in ocular tissues such as the retina in vivo.
We postulated that such a peptide should resemble the glycosaminoglycan binding regions of proteins abundantly present in the retina. Two such proteins are the acidic and basic broblast growth factors. 17 e glycosaminoglycan chondroitan sulphate is known to be abundantly present in adult retina. Heparan sulfate is abundantly expressed during development but its expression is substantially reduced in adult retina. Molecular modeling of protein-glycosaminoglycan interactions of the acidic broblast growth factor and basic broblast growth factor indicates that they contain basic heparin-binding regions of the form XBBBXXBX, where X and B are hydropathic and basic residues, respectively. 18 Following these observations, Verrecchio and colleagues 19 have shown that peptides of the form (XBBBXXBX) n and (XBBXBX) n where n = 1-6, bind heparan. In addition, circular dichroism indicated that heparan-binding peptides converted from a charged coil to an alpha-helix upon heparan binding. We hypothesized that such peptides may have protein transduction properties and tested a variety of sequences for protein transduction (data not shown) prior to the detailed examination of POD presented in this report.
Due to initial controversies surrounding the phenomenon of protein transduction, we have shown that POD enters cells without the need for xation, although xation does lead to an artifact in terms of cellular localization. While we observed primarily cytoplasmic localization in formalin-xed cells within 5 minutes, POD appeared punctate and localized perhaps to endocytic vesicles in live cells even a er 60 minutes. Interestingly, at 1 minute post-incubation with POD, cells became opaque to 558 nm excitation-potentially due to aggregation or capping of cellsurface proteoglycans upon POD binding. 20 Evidence for uptake and not simply plasma membrane binding was demonstrated by treatment of live cells with trypsin, which failed to reduce the uorescence associated with POD-transduced cells. Uptake was also shown to be temperature dependent. One concern in using a peptide such as POD for ocular gene or drug delivery would be potential toxicity during the process of traversing the cell membrane. To address this issue, we demonstrated that there is no increase in the uptake of PI by cells, following incubation with POD. Although additional work needs to be done to demonstrate the lack of toxicity, these initial results are encouraging. While our data support a temperature-dependent mechanism, we found no reduction in peptide uptake in the presence of inhibitors of endocytosis (data not shown). Chlorpromazine reportedly blocks clathrin coated pit-dependent endocytosis and genistein and lipin are known inhibitors of caveolae. However, we found no signi cant reduction in the uptake of L-POD with these inhibitors (data not shown). Our observation that POD can deliver small molecules like siRNA e ciently across the plasma membrane may have implications for the treatment of ocular disease in humans. Currently, there are several ongoing clinical trials that target the degradation of messenger RNA associated with either the vascular endothelial growth factor or its receptor for the treatment of AMD. 21 Indeed, the use of siRNA for treatment of ocular disease in humans is at a particularly advanced stage of development as compared to treatment of other diseases. 22 Since the target of siRNAs is intracellular, e cient delivery across the plasma membrane in a non-toxic manner is highly desirable. POD may potentially enhance siRNA delivery to the retina, allowing for the use of reduced concentrations of siRNA. is can also lead to reduced side e ects such as those associated with non-speci c siRNA mediated silencing. Enhanced delivery of RNA molecules such as the aptamer macugen that is currently used to target vascular endothelial growth factor in the treatment of AMD 23 may also be potentially achieved. POD may also be used to deliver siRNA and DNA in cell culture to study a variety of cellular processes.
Delivery of POD to the subretinal and intravitreal space allowed for penetration of a variety of cell types in the retina. Transduction of photoreceptors can lead to applications in the treatment of diseases such as retinitis pigmentosa whereas transduction of RPE cells can be applied in the treatment of AMD. Conversely, intravitreal injection allowed for the targeting of ganglion cells, the degeneration of which is associated with glaucoma. POD-mediated delivery of growth factors or antiapoptotic factors to the ganglion cells may slow the rate of degeneration of such cells. While quantum dots took substantially longer to penetrate the retina than did L-POD, perhaps due to their larger size, that it was possible to deliver such large molecules is further support for the potential use of POD in the delivery of biologicals to the retina. ese biologicals may include antibodies or antibody fragments such as avastin and lucentis respectively, that are currently also used in the treatment of AMD. 24 One may envision fusion proteins with POD for rapid and enhanced penetration of retinal tissues.
Interestingly, L-POD administered topically reached the dura of the optic nerve within 45 minutes. is may have relevance for the treatment of diseases such as optic nerve sheath meningioma or possibly Leber's hereditary optic neuropathy or ischemic optic neuropathy if POD were to accumulate in the optic nerve itself over time. Penetration of the entire sclera and potentially the choroid may allow for non-invasive delivery of drugs or genes to choroidal blood vessels and endothelial cells, proliferation of which is involved in a variety of ocular diseases including AMD. Topical administration of POD-conjugated drugs to the cornea will also allow enhanced delivery of drugs to the corneal epithelium and into the anterior chamber. is may be particularly useful given that currently very little drug penetrates into ocular tissue following topical administration. 25 Finally, since levels of heparan sulfate are increased in diseased retina, 26 the peptide described in this report may be applied in the treatment of a variety of retinal degenerations.
Several reports have suggested that cell-penetrating peptides may have microbicidal action due to their structural and chemical similarities with naturally occurring antimicrobial peptides. [27] [28] [29] Human immunode ciency virus TAT concentrations of 3-24 µmol/l have been found to be antifungal, resulting from the peptide binding nucleic acids and capable of disrupting the cell cycle. 27 Similarly, Pep-1-K, an analogue of Pep-1 designed speci cally to target microbes, was strongly antibacterial in cultures of Gram-positive and Gram-negative bacteria with a minimal inhibitory concentration of 1-2 µmol/l. e authors of this study suggested Pep-1-K killed the microorganism through the formation of small channels that allow transit of ions or protons. 28 POD appears to have a bacteriostatic activity similar to that of Pep-1-K as it successfully and signicantly reduced the growth of Gram-negative bacteria in culture. However, it is important to note that signi cant reductions in colony number were seen with much lower concentrations of POD than with the other peptides. A concentration as low as 0.3 µmol/l was su cient to reduce E. coli growth, a valuable nding as lower doses of POD are likely to be more clinically applicable. Injections of POD-conjugated to therapeutic agents could possibly provide additional prophylaxis against infections resulting from invasive clinical procedures. 30 Furthermore, the discovery of POD's bacteriostatic activities suggests that the peptide may act as a therapeutic agent on its own, at least for E coli associated endophthalmitis that appears commonly in some parts of the world 31 or randomly in some surgical procedures. 30 Whether POD functions as a bacteriostatic against additional bacterial species or also as a microbicide is currently under investigation.
In summary, in this report we introduce a novel cell-penetrating peptide-POD, and demonstrate its ability to penetrate and deliver uorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo. POD also acts as a microbicide, potentially providing a safer and more e cacious method of delivering molecules to ocular tissues in vivo. Although this has not been examined as yet, it is likely that POD can penetrate cells in other organ systems and hence may also be applied outside the eld of ophthalmology.
MATERIALS AND METHODS

Materials and reagents.
Heparan sulfate, chondroitin sulfate, and PI were purchased from Sigma. GFP Duplex I was purchased from Dharmacon (Lafayette, CO) and pd2-EGFPN1 was from Clontech (Mountain View, CA). N terminal-conjugated peptides (lissamine, biotin, cysteine) with GGG(ARKKAAKA) 4 were custom synthesized and high performance liquid chromatography puri ed by Sigma Genosys (Woodlands, TX). N terminal uorescein isothiocyanate-conjugated GGG(ARKKAAKA) 4 was synthesized by the University of Utah peptide facility. All other commercially available materials and reagents, including the Qdot 655 Streptavidin conjugate, were purchased from Invitrogen (Carlsbad, CA) unless otherwise noted.
Cell-penetrating properties of POD. Unless otherwise stated, all experiments were performed at least twice in triplicate. HER cells were seeded on Lab Tek-II chamber slides and grown to ~70% con uence. Cells were washed twice with phosphate-bu ered saline (PBS) and incubated with 1 nmol L-POD for 0, 5, 15, 30, 45, and 60 minutes or 1 nmol lissamine only for 60 minutes. Cells were xed for 15 minutes in formalin at room temperature. Cells for live imaging were grown on 24-well plates and incubated with 2 nmol of L-POD. Following incubation, cells were washed three times with PBS, incubated in phenol red-free Dulbecco's modi ed
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Eagle's medium supplemented with 2% fetal bovine serum. Cells were visualized by light and uorescent microscopy using either an Olympus IX51 (live cells) or an Olympus BX51 ( xed cells) with di erential interference contrast, RFP, and GFP lters. Images were obtained using a Retiga 2000R FAST camera and QCapture Pro 5.0 (QImaging, British Columbia, Canada). To measure L-POD uptake in the presence of trypsin, 0.2 106 HER cells were incubated with 2.0 nmol L-POD in media for 15 minutes at 37 °C followed by incubation in 2.5 mg/ml trypsin for 12 minutes at 37 °C. For analysis of uptake at 4 °C, cells were cooled to 4 °C for 45 minutes prior to the addition of peptide and cold (4 °C) reagents were used for peptide administration. Following incubation with peptide, cells were washed twice with PBS and spun and resuspended in PBS for FACS analysis. For measurement of membrane permeabilization, HER cells were incubated with 2.0 nmol uorescein isothiocyanate-heparin-binding protein for 30 minutes at 37 °C, washed twice, isolated, and suspended in PBS with 1 µmol/l PI. e number of PI-positive cells was analyzed by FACS. FACS analysis was performed using a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ). Experiments were performed in triplicate and 10,000 events per sample were counted. Results were analyzed using CellQuest Pro soware (Becton Dickinson).
